Zobrazeno 1 - 10
of 1 296
pro vyhledávání: '"ALLAN S. JAFFE"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Allan S Jaffe
Publikováno v:
Biomarkers in Medicine. 17:181-187
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4dbe560add687c6bf29da758526d13d
https://doi.org/10.2217/bmm-2023-0180
https://doi.org/10.2217/bmm-2023-0180
Publikováno v:
American Journal of Preventive Cardiology, Vol 20, Iss , Pp 100886- (2024)
Objective: Lipoprotein(a) [Lp(a)] has been associated with Atherosclerotic Cardiovascular Disease (ASCVD). Approximately 20 % of the population has elevated Lp(a). Despite its well-recognized role in ASCVD, universal screening remains controversial.
Externí odkaz:
https://doaj.org/article/c3c810acb8434b04a647f8db55c3d0ee
Autor:
Anna Wolska, Maureen Sampson, Rafael Zubirán, Jeff W. Meeusen, Leslie J. Donato, Allan S. Jaffe, Alan T. Remaley
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundThe triglyceride (TG) content of low-density lipoprotein (LDL-TG) has been shown to be more predictive of atherosclerotic cardiovascular disease (ASCVD) events than the cholesterol content of LDL (LDL-C). The goal of our study was to develo
Externí odkaz:
https://doaj.org/article/2334aa198b154c47ac13d4b86c56a1af
Autor:
Tatiana C. Coverdell, Maureen Sampson, Rafael Zubirán, Anna Wolska, Leslie J. Donato, Jeff W. Meeusen, Allan S. Jaffe, Alan T. Remaley
Publikováno v:
Lipids in Health and Disease, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Background The accurate measurement of Low-density lipoprotein cholesterol (LDL-C) is critical in the decision to utilize the new lipid-lowering therapies like PCSK9-inhibitors (PCSK9i) for high-risk cardiovascular disease patients that do n
Externí odkaz:
https://doaj.org/article/7403eba74a3b4bc1aba9f686e7990b06
Publikováno v:
Reviews in Cardiovascular Medicine, Vol 25, Iss 11, p 393 (2024)
Lipoprotein a (Lp(a)) is a lipid biomarker that binds cholesterol and bears independent cardiovascular risk. Strategies to lower the level of Lp(a) and mitigate such risk are important both for primary and secondary prevention. Currently there are no
Externí odkaz:
https://doaj.org/article/7222402a69fb47df899eaab2783ffb39
Autor:
Christian Müller, Richard Body, Allan S Jaffe, Gerard Devlin, Richard W Troughton, Sarah J Lord, Nicholas Mills, Peter Kavsak, Louise Cullen, Martin Than, Chris Frampton, John W Pickering, Suzanne Pitama, W Frank Peacock, Sally Aldous, Fred S Apple, Laura Joyce, Cameron James Lacey, Arthur M Richards
Publikováno v:
BMJ Open, Vol 14, Iss 6 (2024)
Introduction Clinical assessment in emergency departments (EDs) for possible acute myocardial infarction (AMI) requires at least one cardiac troponin (cTn) blood test. The turn-around time from blood draw to posting results in the clinical portal for
Externí odkaz:
https://doaj.org/article/14250be12aa0419fb2bc5a7b80448321
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 21 (2023)
Externí odkaz:
https://doaj.org/article/2185439c20fa4154b87b3a524b136622
Autor:
Allan S. Jaffe
Publikováno v:
Coronary Artery Disease. 3:1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::707e7261df835f762a47ebae079bc22b
https://doi.org/10.1097/00019501-199201000-00001
https://doi.org/10.1097/00019501-199201000-00001
Autor:
Maureen Sampson, Anna Wolska, Jeff W. Meeusen, Leslie J. Donato, Allan S. Jaffe, Alan T. Remaley
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Dysbetalipoproteinemia (hyperlipoproteinemia type III, HLP3) is a genetic disorder that results in the accumulation of cholesterol on highly atherogenic remnant particles. Traditionally, the diagnosis of HLP3 depended upon lipoprotein gel electrophor
Externí odkaz:
https://doaj.org/article/f5948ef2ff174bbe92393875f9c7a771